Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal

Dow Jones

04/27

By Katherine Hamilton

Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.

Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.

Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.

Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.

It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.

Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

April 27, 2026 08:08 ET (12:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2630967713"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630967713\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630967713?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630967713","market":"us","top_or_hot":-1,"title":"Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Therapeutics Bile Cancer Treatment Doesn't Meet Overall Survival Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-27 20:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Compass <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n</p>\n<p>\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n</p>\n<p>\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n</p>\n<p>\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n</p>\n<p>\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n</p>\n<p>\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 27, 2026 08:08 ET (12:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPX","symbol_name":"Compass Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2630967713","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630967713","pubTimestamp":1777291680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival.Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year.Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder.Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%.It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial.Because of the high crossover rate, the data from the trial are uninterpretable, Compass said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPX":"Compass Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Compass Therapeutics胆汁癌治疗未达到总生存目标","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPX":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. \n\n\n  Shares fell 23% to $3.85 in premarket trading Monday. Through Friday's close, the stock was down 6% this year. \n\n\n  Compass' trial was studying tovecimig plus paclitaxel as a treatment of biliary tract cancer, which affects the bile ducts or gallbladder. \n\n\n  Tovecimig showed a clinically meaningful and statistically significant improvement in progression-free survival. It reduced the risk of disease progression by 56%. \n\n\n  It didn't meet the overall survival endpoint, however, due to high crossover from the control arm. About 54% of patients crossed over from the control group to receive the treatment that was being studied in the trial. \n\n\n  Because of the high crossover rate, the data from the trial are uninterpretable, Compass said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 08:08 ET (12:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}